ObjectiveTo evaluate the performance of the disk diffusion test with lefamulin 20 µg compared with the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method. Methods572 clinical stains, including 240 Staphylococcus aureus, 211 Streptococcus pneumoniae and 121 Haemophilus influenzae, isolated from 71 medical centers from the China Antimicrobial Surveillance Network (CHINET) in 2020. Broth microdilution method and disk diffusion methods were performed according to CLSI. Categorical agreement (CA), major error (ME), and very major error (VME) were calculated. ResultsLefamulin showed potent activity against S. aureus, S. pneumoniae, and H. influenzae. Using the broth microdilution method, lefamulin inhibited 97.1% of S. aureus isolates at 0.25 mg/L; seven isolates were not susceptible. For S. pneumoniae and H. influenzae, the percentage of susceptibility to lefamulin was 100% and no non-susceptible strains were found in this study. Compared with the reference broth microdilution method, the CA of the lefamulin 20 µg disk testing was 99.8% (571/572), with 14.3% (1/7) VME and no ME. In our study, VME was determined in S. aureus. For S. pneumoniae and H. influenzae, the VME was not determined due to the lack of lefamulin non-susceptible strains. ConclusionThe lefamulin 20 µg disk diffusion testing showed excellent CA and ME with the reference broth microdilution method for S. aureus, S. pneumoniae, and H. influenzae. The VME exceeding CLSI recommendations may be a bias due to fewer lefamulin non-susceptible isolates. Our results suggest that lefamulin non-susceptible isolates detected by disk diffusion should be confirmed by the reference BMD.
Read full abstract